<code id='236C7F85EA'></code><style id='236C7F85EA'></style>
    • <acronym id='236C7F85EA'></acronym>
      <center id='236C7F85EA'><center id='236C7F85EA'><tfoot id='236C7F85EA'></tfoot></center><abbr id='236C7F85EA'><dir id='236C7F85EA'><tfoot id='236C7F85EA'></tfoot><noframes id='236C7F85EA'>

    • <optgroup id='236C7F85EA'><strike id='236C7F85EA'><sup id='236C7F85EA'></sup></strike><code id='236C7F85EA'></code></optgroup>
        1. <b id='236C7F85EA'><label id='236C7F85EA'><select id='236C7F85EA'><dt id='236C7F85EA'><span id='236C7F85EA'></span></dt></select></label></b><u id='236C7F85EA'></u>
          <i id='236C7F85EA'><strike id='236C7F85EA'><tt id='236C7F85EA'><pre id='236C7F85EA'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          comprehensive

          author:Wikipedia    - browse:41964

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          hotspot